📷 Image: Wikimedia Commons / Original: Vyacheslav Argenberg
Derivative work:
Business
GOA Therapeutics Secures $15.5 M Funding, Unveils GOA26 for Acute Alcohol Poisoning
✍️ The Manila Times
🗓 18 Sep 2026, 04:16 AM
👁 7
The Manila‑based biotech GOA Therapeutics announced it has raised $15.5 million in its first financing round and introduced GOA26, a novel drug aimed at treating acute alcohol intoxication and poisoning.
GOA Therapeutics, a biotechnology firm that has operated in stealth mode until now, disclosed that it closed a $15.5 million funding round. The capital injection is intended to accelerate the development of its pipeline, beginning with the flagship candidate GOA26.
GOA26 is described as a first‑in‑class molecule designed to rapidly reverse the physiological effects of acute alcohol intoxication and poisoning. Researchers say the compound works by targeting specific pathways involved in alcohol metabolism, offering a potential emergency treatment for severe cases.
The company, headquartered in Manila, said the new financing will support pre‑clinical studies and preparation for regulatory submissions. While details of the investors were not disclosed, the funding marks the firm’s first public appearance and signals confidence in its innovative approach.
If successful, GOA26 could fill a therapeutic gap in emergency medicine, where few options exist to quickly mitigate life‑threatening alcohol toxicity. GOA Therapeutics plans to publish further data as the drug advances through development stages.
GOA26 is described as a first‑in‑class molecule designed to rapidly reverse the physiological effects of acute alcohol intoxication and poisoning. Researchers say the compound works by targeting specific pathways involved in alcohol metabolism, offering a potential emergency treatment for severe cases.
The company, headquartered in Manila, said the new financing will support pre‑clinical studies and preparation for regulatory submissions. While details of the investors were not disclosed, the funding marks the firm’s first public appearance and signals confidence in its innovative approach.
If successful, GOA26 could fill a therapeutic gap in emergency medicine, where few options exist to quickly mitigate life‑threatening alcohol toxicity. GOA Therapeutics plans to publish further data as the drug advances through development stages.